Work

The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.4567

Authors: Martin Henner Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Musa Mutyaba, Kristen M. Pappas, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi Sumant Pandya

Institutions: Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Cleveland Clinic, Georgetown Lombardi Comprehensive Cancer Center, Hackensack University Medical Center, Beth Israel Deaconess Medical Center, Highlands Oncology Group, Acceleron Pharma (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2344760833

Cites:

Cited by: 5

Related to: 10